Background: BRCA mutations result in a variety of cancer types such as breast, ovarian, and prostate. 4-40% of the patients with male breast cancer have BRCA mutations, and BRCA 2 mutation is more commonly detected. In this study, we compared the clinicopathological characteristics of BRCA- wild type and -mutated male breast cancer (MBC).
Methods: The data of 43 patients were retrospectively reviewed. Clinical and histopathological data of the patients were recorded. The characteristics of the patients were compared by the chi-square test and Fisher exact test. Survival analysis evaluated with Kaplan-Meier analysis.
Results: The median follow-up period was 35.8 months (range, 2.2-225.8). The median age at diagnosis was 58 years (range, 25-81) and not statistically different between groups (p=0.753). 11 (25.6%) of the patients had BRCA mutations. Four (9.3%) patients had BRCA1 mutations, six (14%) patients BRCA2 mutations, and one (2.3%) patients had both BRCA 1 and 2 mutations. Among BRCA- wild type and - mutated patients: estrogen receptor positivity (p=0.055), progesterone receptor positivity (p=0.698), HER2 overexpression (p=0.542), tumor localization (p=0.305), tumor histology (p=0.069), lymph node involvement (p=0.589), tumor stage (p=0.892), and recurrence status (p=0.698) were comparable. The median overall survival was 115.6 months (range, 76.0-155.3), and similar between groups (p=0.647).
Conclusions: MBC is rare. In literature, the data of MBC and BRCA mutation is limited, and studies included a low number of patients. In a result, we found that clinicopathological characteristic and prognosis of BRCA-mutated and-wild type MBC was similar.
Citation Format: Izzet Dogan, Esra Aydın, Hülya Yazıcı, Pınar Saip. Comparison of clinicopathological features in BRCA-wild type and -mutated male breast cancer patients [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS14-26.